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A C C E P T E D M
A N U S C R I P T models were used to identify predictors of anal and oral HPV.
Results:
A total of 214 of 334 WLWH had sufficient DNA for analysis at all three anatomical sites and were included in analyses. Cervical, oral, and anal high-risk (hr) HPV prevalence were 28.0%, 3.7% and A C C E P T E D M A N U S C R I P T 3 39.3%. Most frequent i) cervical, ii) oral and iii) anal hrHPV genotypes were i) hrHPV58 (8.4%), 52
(5.1%), 16 (5.1%) and 51 (5.1%); ii) 52 (1.4%) and iii) 51 (9.3%), 58 (8.9%), 16 (7.0%) and 18 (7.0%).
Among present cervical, oral, and anal hrHPV genotypes, 6.7%, 12.5% and 17.9% were targeted by the 2-or 4-valent HPV vaccines, whereas 50.0%, 50.0% and 42.9% of hrHPV genotypes were covered by the 9-valent HPV vaccine. Anal HPV infection was predicted by cervical HPV infection (adjusted OR 4.47 (95%CI 2.25-8.89)).
Conclusion:
Cervical and anal HPV infection were highly prevalent in WLWH. Non-16/18 hrHPV genotypes were predominant at all anatomical sites. Almost half of all hrHPV infections at the three anatomical sites could have been prevented by childhood/adolescent vaccination with the 9-valent HPV vaccine. Women living with HIV; human papillomavirus; cervical cancer, anal cancer; oral cancer; genotype distribution; HPV vaccine, concordance, HPV prevalence.
Background
Five percent of the world's cancer burden is attributable to human papillomavirus (HPV) infection [1] , and people living with HIV (PLWH) have elevated risk of HPV related cancers at different anatomical sites, compared to their HIV-negative peers [2] [3] [4] . Especially increased risk of HPVrelated cervical cancer (CC) [2, [5] [6] [7] [8] [9] , oropharyngeal cancer (OPC) [5, 10, 11] , and anal cancer (AC) [5, 12] has been reported [2, [5] [6] [7] [8] [9] . Whereas HPV is the causal agent of CC, the prevalence of HPV in
OPCs is 25-46% [13, 14] and 58-100% in ACs [15, 16] .
A C C E P T E D M
A N U S C R I P T 
Objectives
The aim of the present study was to assess the prevalence, distribution and concordance of cervical, oral, and anal HPV in WLWH in Denmark. Furthermore, we aimed at identifying predictors of oral and anal HPV.
Study design: Setting
Denmark has a population of 5.7 million [29] and an estimated HIV prevalence among adults of 0.1% [30] . Medical care, including ART, is tax-paid and provided free-of-charge to all PLWH [22] . 
The SHADE cohort
The SHADE cohort is an ongoing, multicentre, prospective, observational cohort study of WLWH in Denmark attending regular outpatient care for HIV infection. Briefly, study participants were enrolled during outpatient visits from 1 February 2011-1 February 2012. Inclusion criteria were known HIV-1 infection and ≥18 years of age. Exclusion criteria were pregnancy, prior hysterectomy (due to CC or other reasons), and/or alcohol or drug abuse impeding adherence to protocol.
Previous and current lesions related to HPV infection, such as condyloma acuminata, and prior treatment for this, were not an exclusion criterion. A full description of the cohort has previously been published [34] .
Interview survey
Written informed consent was obtained at study entry and a standardized interview among others regarding smoking, age at sexual debut, lifetime sexual partners, and contraceptive use was
performed (Supplementary file 1). Double manual data entry of the questionnaires was performed using the EpiData Entry program [35] .
Registries

Civil Registration System (CRS)
The CRS is a national registry of all Danish residents [36] . A unique personal identification number (PIN) is assigned to each individual. This PIN was used to link to the Danish HIV Cohort Study (DHCS).
Danish HIV Cohort Study (DHCS)
HIV demographics were retrieved from the DHCS, which is a prospective, observational, nationwide, multicentre, population-based cohort study of all PLWH seen at the Danish HIV clinics since 1 January 1995 [31].
Sample collection & HPV DNA testing
A trained doctor collected cervical, oral and anal HPV samples using flocked swabs (UTM-RT viral transport media Flocked Polyester Swabs, Copan Diagnostics, Inc., Murrieta, CA). Cervical samples were collected by inserting a cytobrush through a speculum and rotating it in the cervical canal.
Oral samples were collected from the tonsils and posterior pharynx by means of firm strokes of a cytobrush on both sides. Finally, a cytobrush was inserted into the anal canal and rotated while applying gentle pressure to the walls of the canal to collect anal epithelial cells. Samples were stored at room temperature and transported to the Department of Pathology, Copenhagen University Hospital, Hvidovre. Samples were analysed for HPV using the CLART HPV2 assay Overall, 95.3% of the patients were on ART and 80.6% of these had HIV-RNA<40 copies/mL (Table   1) .
Cervical, oral and anal HPV prevalence
Overall cervical, oral, and anal HPV prevalence was 50.5%, 5.6% and 63.1% (cervical versus oral;
p<0.0001, cervical versus anal; p<0.0021) ( Table 2) , hrHPV prevalence was 28.0%, 3.7% and 39.3%
(cervical versus oral; p<0.0001; cervical versus anal; p=0.0013). Multiple cervical HPV infections were more frequent than oral (mean 1.1, range 0-9 vs. mean 0.1, range 0-6), but less frequent than anal co-infections (mean 1.5, range 0-14) ( Table 2) .
Cervical, oral, and anal concordance
We found no concordance between cervical and oral HPV findings, but anal HPV prevalence was positively correlated with cervical HPV infection (Table 2) .
Cervical, oral, and anal genotype distribution
Most frequent cervical hrHPV genotypes observed were hrHPV58 (n=18, 8.4%), 52 (n=11, 5.1%), 16 (n=11, 5.1%) and 51 (n=11, 5.1%) ( Figure 1 , Table 3 ). HrHPV 52 (n=3, 1.4%) was the most frequent oral hrHPV infection. Other orally observed hrHPV infections were only present once ( Figure 1 , Table 3 ). Most frequent anal hrHPV genotypes were hrHPV51 (n=20, 9.3%), 58 (n=19,
8.9%), 16 (n=15, 7.0%) and 18 (n=15, 7.0%) ( Figure 1 , Table 3 ). Table 2 summarizes to which extent the observed genotypes were covered by the 2-or 4-valent HPV vaccine. Cervical, oral, and anal lrHPV genotype distribution is presented in Figure 1 and Table 3 .
Predictors of oral and anal HPV
We found no predictors of overall oral HPV infection (Supplementary file 2). Overall anal HPV infection was associated with cervical HPV infection (adjusted OR per year 4.47 (95%CI 2.25-8.89)) (Table 4) . In adjusted analyses, we found no predictors of anal hrHPV (data not shown).
Discussion
In this multicentre, cross-sectional cohort study of WLWH in Denmark, more than half of WLWH were concurrently cervical and anal HPV positive, and a large proportion presented with multiple anogenital HPV infections. A correlation between cervical and anal hr-and lrHPV was observed and cervical HPV infection predicted anal HPV infection. Non-16/18 hrHPV genotypes were
predominant at all anatomical sites. Almost half the present hrHPV genotypes would have been covered by the 9-valent HPV vaccine.
Cervical HPV prevalence
Cervical HPV prevalence was 50.5% overall with a hrHPV prevalence of 28.0%, which is substantially higher than found amongst women participating in the Danish cervical screening program (hrHPV prevalence between 9.4-16.2% dependent on the assay used) [42] .
Oral HPV prevalence
Little 
Anal HPV prevalence
Anal HPV and hrHPV prevalence was 63.1% and 39.3%. The higher prevalence in WLWH of anal compared with cervical hrHPV, is similar to other reports [23, 44] . Moreover, anal hrHPV prevalence is higher in WLWH compared with HIV-negative women [45, 46] . In WLWH, studies
have found an overall anal HPV and hrHPV prevalence of 75. 
Strengths and limitations
Strengths include the well-characterized cohort and the use of nationwide registries. Furthermore, HPV analyses were performed routinely in a high throughput, quality controlled and quality assured clinical laboratory using a well-characterized HPV assay. Limitations include the rather high number of inadequate samples. One study found that oral rinse samples were significantly more sensitive than self-collected swabs in order to obtain analytically sufficient oral samples [55] .
However, the use of cytobrushes, as done in the present study, allows for retrieval of cells from 
Conclusion
Systematically generated evidence of HPV infection in cohorts of PLWH can help shape primary and secondary HPV related cancer prevention. Here we present data from a Danish cohort of WLWH, demonstrating that more than half had cervical and anal HPV infection with a large proportion presenting with multiple, concurrent anogenital HPV infections. Non-16/18 hrHPV genotypes were predominant, which renders the 2-and 4-valent HPV vaccines less effective than the 9-valent HPV vaccine. Regarding secondary prevention, evidence of benefit is still insufficient regarding OPC and AC screening, but these data support continued focus on CC screening in WLWH.
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